Serological Status of Vaccine and Hepatitis B Virus Exposure Among Children Under 5 and Aged 15–17 Years in Kampala, Uganda
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design, Population, and Settings
2.2. Inclusion and Exclusion Criteria
2.3. Sample Size Estimation and Sampling Procedure
2.4. Data Collection Procedures
2.5. Sample Collection and Processing
2.6. Laboratory Analysis
2.7. Data Analysis
2.8. Interpretation of the Hepatitis B Serological Test Results
3. Results
3.1. Socio-Demographic Characteristics
3.2. Concordance Among NOVA TEST, Fastep, and Beright Diagnostic Rapid Tests
3.3. Doses of Hepatitis B Vaccine Received
3.4. Qualitative Anti-HBs Status and Prevalence of HBV Infection Among Study Groups
4. Discussion
5. Conclusions
6. Limitations
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Hsu, Y.-C.; Huang, D.Q.; Nguyen, M.H. Global burden of hepatitis B virus: Current status, missed opportunities and a call for action. Nat. Rev. Gastroenterol. Hepatol. 2023, 20, 524–537. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization. Global Hepatitis Report 2017; World Health Organization: Geneva, Switzerland, 2017. [Google Scholar]
- Razavi-Shearer, D.; Gamkrelidze, I.; Nguyen, M.H.; Chen, D.-S.; Van Damme, P.; Abbas, Z.; Abdulla, M.; Abou Rached, A.; Adda, D.; Aho, I. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study. Lancet Gastroenterol. Hepatol. 2018, 3, 383–403. [Google Scholar] [CrossRef] [PubMed]
- Ochola, E.; Ocama, P.; Orach, C.G.; Nankinga, Z.K.; Kalyango, J.N.; McFarland, W.; Karamagi, C. High burden of hepatitis B infection in Northern Uganda: Results of a population-based survey. BMC Public Health 2013, 13, 727. [Google Scholar] [CrossRef] [PubMed]
- Safadi, R.; Khoury, T.; Saed, N.; Hakim, M.; Jamalia, J.; Nijim, Y.; Farah, N.; Nuser, T.; Natur, N.; Mahamid, M. Efficacy of birth dose vaccination in preventing mother-to-child transmission of hepatitis B: A randomized controlled trial comparing Engerix-B and Sci-B-Vac. Vaccines 2021, 9, 331. [Google Scholar] [CrossRef]
- de Villiers, M.J.; Nayagam, S.; Hallett, T.B. The impact of the timely birth dose vaccine on the global elimination of hepatitis B. Nat. Commun. 2021, 12, 6223. [Google Scholar] [CrossRef]
- Akbar, S.M.F.; Al Mahtab, M.; Begum, F.; Hossain, S.A.S.; Sarker, S.; Shrestha, A.; Khan, M.S.I.; Yoshida, O.; Hiasa, Y. Implications of birth-dose vaccination against hepatitis B virus in Southeast Asia. Vaccines 2021, 9, 374. [Google Scholar] [CrossRef]
- Memirie, S.T.; Desalegn, H.; Naizgi, M.; Nigus, M.; Taddesse, L.; Tadesse, Y.; Tessema, F.; Zelalem, M.; Girma, T. Introduction of birth dose of hepatitis B virus vaccine to the immunization program in Ethiopia: An economic evaluation. Cost Eff. Resour. Alloc. 2020, 18, 23. [Google Scholar] [CrossRef]
- Sahana, H.; Sarala, N.; Prasad, S. Decrease in anti-HBs antibodies over time in medical students and healthcare workers after hepatitis B vaccination. BioMed Res. Int. 2017, 2017, 1327492. [Google Scholar] [CrossRef]
- Yang, S.; Tian, G.; Cui, Y.; Ding, C.; Deng, M.; Yu, C.; Xu, K.; Ren, J.; Yao, J.; Li, Y. Factors influencing immunologic response to hepatitis B vaccine in adults. Sci. Rep. 2016, 6, 27251. [Google Scholar] [CrossRef]
- Tripathy, S.; Sati, H.; Puspa, S.S.; Shankar, R.; Singh, V. Study of immune response after hepatitis B vaccination in medical students and health care workers. Indian J. Prev. Soc. Med. 2011, 42, 315–321. [Google Scholar]
- Nashibi, R.; Alavi, S.M.; Yousefi, F.; Salmanzadeh, S.; Moogahi, S.; Ahmadi, F.; Farashahinejad, M. Post-vaccination immunity against hepatitis B virus and predictors for non-responders among medical staff. Jundishapur J. Microbiol. 2015, 8, e19579. [Google Scholar] [CrossRef]
- Adugna, A.; Demeke, G.; Toru, M.; Tsehay, D.; Esmael, A.; Mihret, A.; Mulu, A. Reduced protective efficacy of hepatitis B vaccine among fully vaccinated children in Ethiopia. PLoS ONE 2023, 18, e0288355. [Google Scholar] [CrossRef] [PubMed]
- Alemayehu, T.; Daba, M.D.; Buonsenso, D. Long-Term Hepatitis B Vaccine Immunity in Ethiopian Children That Received a Pentavalent Vaccine Series: A Retrospective Cohort Study. Children 2024, 11, 136. [Google Scholar] [CrossRef] [PubMed]
- Leuridan, E.; Van Damme, P. Hepatitis B and the need for a booster dose. Clin. Infect. Dis. 2011, 53, 68–75. [Google Scholar] [CrossRef]
- Yonghao, G.; Jin, X.; Jun, L.; Pumei, D.; Ying, Y.; Xiuhong, F.; Yanyang, Z.; Wanshen, G. An epidemiological serosurvey of hepatitis B virus shows evidence of declining prevalence due to hepatitis B vaccination in central China. Int. J. Infect. Dis. 2015, 40, 75–80. [Google Scholar] [CrossRef]
- Kedir, R.; Taye, B.D.; Kassa, T.; Teshager, L.; Aseffa, A.; Howe, R.; Mihiret, A.; Gezie, A. Seroprevalence of hepatitis B virus infection and seroprotection of hepatitis B vaccine among children in Jimma town, southwest Ethiopia. Ethiop. Med. J. 2019, 57, 147–158. Available online: https://pesquisa.bvsalud.org/portal/resource/pt/afr-201256 (accessed on 30 July 2021).
- Shih, H.-H.; Chang, M.-H.; Hsu, H.-Y.; Lee, P.-I.; Ni, Y.-H.; Chen, D.-S. Long term immune response of universal hepatitis B vaccination in infancy: A community-based study in Taiwan. Pediatr. Infect. Dis. J. 1999, 18, 427–432. [Google Scholar] [CrossRef]
- Huang MeiLiang, H.M.; Liao WenLing, L.W.; Ho MeiShang, H.M. HBV serological markers of vaccinated children in remote areas of Taiwan: Emphasis on factors contributing to vaccine failure. Vaccine 2007, 25, 6326–6333. [Google Scholar] [CrossRef] [PubMed]
- Muwanda, F.; Sendagire, H.; Mboowa, G.; Kateete, D.P.; Achan, B.; Mupere, E.; Kafeero, H.M.; Bagaya, B.S. A systematic review reveals that African children of 15–17 years demonstrate low hepatitis B vaccine seroprotection rates. Sci. Rep. 2023, 13, 22182. [Google Scholar] [CrossRef]
- Eladawy, M.; Gamal, A.; Fouad, A.; El-Faramawy, A. Hepatitis B Virus Vaccine immune response in Egyptian children 15–17 years after primary immunization; should we provide a booster dose? Egypt. J. Pediatr. Allergy Immunol. 2015, 13, 45–48. [Google Scholar]
- Chaouch, H.; Hachfi, W.; Fodha, I.; Kallala, O.; Saadi, S.; Bousaadia, A.; Lazrag, F.; Bougmiza, I.; Aouni, M.; Trabelsi, A. Impact and long-term protection of hepatitis B vaccination: 17 years after universal hepatitis B vaccination in Tunisia. Epidemiol. Infect. 2016, 144, 3365–3375. [Google Scholar] [CrossRef] [PubMed]
- Makhlouf, N.A.; Farghaly, A.M.; Zaky, S.; Rashed, H.A.G.; Abu Faddan, N.H.; Sayed, D.; El-Badawy, O.; Afifi, N.; Hamza, W.S.; El-Sayed, Y. The efficacy of hepatitis B vaccination program in upper Egypt: Flow cytometry and the evaluation of long term immunogenicity. J. Med. Virol. 2016, 88, 1567–1575. [Google Scholar] [CrossRef]
- Malande, O.O.; Munube, D.; Afaayo, R.N.; Annet, K.; Bodo, B.; Bakainaga, A.; Ayebare, E.; Njunwamukama, S.; Mworozi, E.A.; Musyoki, A.M. Barriers to effective uptake and provision of immunization in a rural district in Uganda. PLoS ONE 2019, 14, e0212270. [Google Scholar] [CrossRef]
- World Health Organization. WHO Country Cooperation Strategy 2016–2020: Uganda; World Health Organization: Geneva, Switzerland, 2016. [Google Scholar]
- Bwogi, J.; Braka, F.; Makumbi, I.; Mishra, V.; Bakamutumaho, B.; Nanyunja, M.; Opio, A.; Downing, R.; Biryahwaho, B.; Lewis, R.F. Hepatitis B infection is highly endemic in Uganda: Findings from a national serosurvey. Afr. Health Sci. 2009, 9, 98–108. [Google Scholar]
- Kitandwe, P.K.; Muyanja, E.; Nakaweesa, T.; Nanvubya, A.; Ssetaala, A.; Mpendo, J.; Okech, B.; Bagaya, B.S.; Kiwanuka, N.; Price, M.A. Hepatitis B prevalence and incidence in the fishing communities of Lake Victoria, Uganda: A retrospective cohort study. BMC Public Health 2021, 21, 394. [Google Scholar] [CrossRef] [PubMed]
- Ocan, M.; Acheng, F.; Otike, C.; Beinomugisha, J.; Katete, D.; Obua, C. Antibody levels and protection after Hepatitis B vaccine in adult vaccinated healthcare workers in northern Uganda. PLoS ONE 2022, 17, e0262126. [Google Scholar] [CrossRef]
- Ssekamatte, T.; Mukama, T.; Kibira, S.P.; Ndejjo, R.; Bukenya, J.N.; Kimoga, Z.P.A.; Etajak, S.; Nuwematsiko, R.; Buregyeya, E.; Ssempebwa, J.C. Hepatitis B screening and vaccination status of healthcare providers in Wakiso district, Uganda. PLoS ONE 2020, 15, e0235470. [Google Scholar] [CrossRef]
- Kalton, G.; Heeringa, S. Leslie Kish: Selected Papers; John Wiley & Sons: Hoboken, NJ, USA, 2003; Volume 330. [Google Scholar]
- Langton, S.; Chevennement, R.; Nagelkerke, N.; Lombard, B. Analysing collaborative trials for qualitative microbiological methods: Accordance and concordance. Int. J. Food Microbiol. 2002, 79, 175–181. [Google Scholar] [CrossRef]
- World Health Organization. Interim Guidance for Country Validation of Viral Hepatitis Elimination; World Health Organization: Geneva, Switzerland, 2021. [Google Scholar]
- Lewis, R.F.; Kisakye, A.; Gessner, B.D.; Duku, C.; Odipio, J.B.; Iriso, R.; Nansera, D.; Braka, F.; Makumbi, I.; Kekitiinwa, A. Action for child survival: Elimination of Haemophilus influenzae type b meningitis in Uganda. Bull. World Health Organ. 2008, 86, 292–301. [Google Scholar] [CrossRef]
- World Health Organization. WHO/UNICEF Estimates of National Immunization Coverage; World Health Organization: Geneva, Switzerland, 2010; pp. 2–24. [Google Scholar]
- World Health Organization. Hepatitis B Vaccination Coverage. Available online: https://immunizationdata.who.int/global/wiise-detail-page/hepatitis-b-vaccination-coverage (accessed on 30 July 2021).
- World Health Organization. WHO AFRO Immunization Bulletin; World Health Organization: Geneva, Switzerland, 2020; Volume 8, pp. 1–13. Available online: https://www.afro.who.int/publications/who-afro-immunization-bulletin-vol-8-issue-ndeg-1-january-august-2020 (accessed on 30 July 2021).
- Kabore, H.J.; Li, X.; Allison, R.D.; Avagyan, T.; Mihigo, R.; Takashima, Y.; Tohme, R.A. Effects of decreased immunization coverage for hepatitis B virus caused by COVID-19 in World Health Organization Western Pacific and African Regions, 2020. Emerg. Infect. Dis. 2022, 28 (Suppl. 1), S217. [Google Scholar] [CrossRef]
- Jack, A.; Hall, A.; Maine, N.; Mendy, M.; Whittle, H. What level of hepatitis B antibody is protective? J. Infect. Dis. 1999, 179, 489–492. [Google Scholar] [CrossRef] [PubMed]
- Lu, C.Y.; Chiang, B.L.; Chi, W.K.; Chang, M.H.; Ni, Y.H.; Hsu, H.M.; Twu, S.J.; Su, I.J.; Huang, L.M.; Lee, C.Y. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology 2004, 40, 1415–1420. [Google Scholar] [CrossRef]
- McMahon, B.J.; Bruden, D.L.; Petersen, K.M.; Bulkow, L.R.; Parkinson, A.J.; Nainan, O.; Khristova, M.; Zanis, C.; Peters, H.; Margolis, H.S. Antibody levels and protection after hepatitis B vaccination: Results of a 15-year follow-up. Ann. Intern. Med. 2005, 142, 333–341. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization. Hepatitis B vaccines: WHO position paper-July 2017. Wkly. Epidemiol. Rec. 2017, 92, 369–392. [Google Scholar]
- Canton, H. World Health Organization—WHO. In The Europa Directory of International Organizations 2021; Routledge: London, UK, 2021; pp. 370–384. [Google Scholar]
- Hammitt, L.L.; Hennessy, T.W.; Fiore, A.E.; Zanis, C.; Hummel, K.B.; Dunaway, E.; Bulkow, L.; McMahon, B.J. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: A follow-up study at 15 years. Vaccine 2007, 25, 6958–6964. [Google Scholar] [CrossRef] [PubMed]
- Ni, Y.H.; Huang, L.M.; Chang, M.H.; Yen, C.J.; Lu, C.Y.; You, S.L.; Kao, J.H.; Lin, Y.C.; Chen, H.L.; Hsu, H.Y. Two decades of universal hepatitis B vaccination in Taiwan: Impact and implication for future strategies. Gastroenterology 2007, 132, 1287–1293. [Google Scholar] [CrossRef]
- Lin, A.W.-C.; Wong, K.-H. Surveillance and response of hepatitis B virus in Hong Kong Special Administrative Region, 1988–2014. West. Pac. Surveill. Response J. WPSAR 2016, 7, 24. [Google Scholar] [CrossRef]
- Norizuki, M.; Kitamura, T.; Komada, K.; Sugiyama, M.; Mizokami, M.; Xeuatvongsa, A.; Som-Oulay, V.; Vongphrachanh, P.; Machida, M.; Wada, K. Serologic testing of randomly selected children after hepatitis B vaccination: A cross-sectional population-based study in Lao People’s Democratic Republic. BMC Infect. Dis. 2019, 19, 507. [Google Scholar] [CrossRef]
- Anutebeh, E.N.; Tatah, L.; Feteh, V.F.; Aroke, D.; Assob, J.C.; Choukem, S.P. Immune response to hepatitis B vaccine following complete immunization of children attending two regional hospitals in the Southwest region of Cameroon: A cross sectional study. BMC Infect. Dis. 2021, 21, 1205. [Google Scholar] [CrossRef]
- Alssamei, F.A.; Al-Sonboli, N.A.; Alkumaim, F.A.; Alsayaad, N.S.; Al-Ahdal, M.S.; Higazi, T.B.; Elagib, A.A. Assessment of immunization to hepatitis B vaccine among children under five years in rural areas of Taiz, Yemen. Hepat. Res. Treat. 2017, 2017, 2131627. [Google Scholar] [CrossRef]
- Tfifha, M.; Kacem, S.; Ben Rejeb, M.; Naija, S.; Boujaafar, N.; Abroug, S.; Trabelsi, A. Evaluation of antibody persistence after a four-dose primary hepatitis B vaccination and anamnestic immune response in children under 6 years. J. Med. Microbiol. 2019, 68, 1686–1693. [Google Scholar] [CrossRef] [PubMed]
- Prabdial-Sing, N.; Makhathini, L.; Smit, S.B.; Manamela, M.J.; Motaze, N.V.; Cohen, C.; Suchard, M.S. Hepatitis B sero-prevalence in children under 15 years of age in South Africa using residual samples from community-based febrile rash surveillance. PLoS ONE 2019, 14, e0217415. [Google Scholar] [CrossRef]
- Madhi, S.A.; López, P.; Zambrano, B.; Jordanov, E.; B’Chir, S.; Noriega, F.; Feroldi, E. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Hum. Vaccines Immunother. 2019, 15, 658–668. [Google Scholar] [CrossRef] [PubMed]
- Quaye, T.; Narkwa, P.W.; Domfeh, S.A.; Kattah, G.; Mutocheluh, M. Immunosurveillance and molecular detection of hepatitis B virus infection amongst vaccinated children in the West Gonja District in Savanna Region of Ghana. PLoS ONE 2021, 16, e0257103. [Google Scholar] [CrossRef] [PubMed]
- Rey-Cuille, M.-A.; Seck, A.; Njouom, R.; Chartier, L.; Sow, H.D.; Mamadou; Ka, A.S.; Njankouo, M.; Rousset, D.; Giles-Vernick, T. Low immune response to hepatitis B vaccine among children in Dakar, Senegal. PLoS ONE 2012, 7, e38153. [Google Scholar] [CrossRef]
- Zhao, Y.-L.; Han, B.-H.; Zhang, X.-J.; Pan, L.-L.; Zhou, H.-S.; Gao, Z.; Hao, Z.-Y.; Wu, Z.-W.; Ma, T.-L.; Wang, F. Immune persistence 17 to 20 years after primary vaccination with recombination hepatitis B vaccine (CHO) and the effect of booster dose vaccination. BMC Infect. Dis. 2019, 19, 482. [Google Scholar] [CrossRef]
- Romanò, L.; Galli, C.; Tagliacarne, C.; Tosti, M.E.; Velati, C.; Fomiatti, L.; Chironna, M.; Coppola, R.C.; Cuccia, M.; Mangione, R. Persistence of immunity 18–19 years after vaccination against hepatitis B in 2 cohorts of vaccinees primed as infants or as adolescents in Italy. Hum. Vaccines Immunother. 2017, 13, 981–985. [Google Scholar] [CrossRef]
- Whittle, H.; Jaffar, S.; Wansbrough, M.; Mendy, M.; Dumpis, U.; Collinson, A.; Hall, A. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 2002, 325, 569. [Google Scholar] [CrossRef]
- Mendy, M.; Peterson, I.; Hossin, S.; Peto, T.; Jobarteh, M.L.; Jeng-Barry, A.; Sidibeh, M.; Jatta, A.; Moore, S.E.; Hall, A.J. Observational study of vaccine efficacy 24 years after the start of hepatitis B vaccination in two Gambian villages: No need for a booster dose. PLoS ONE 2013, 8, e58029. [Google Scholar] [CrossRef]
- Mangowi, I.; Mirambo, M.M.; Kilonzo, S.B.; Mlewa, M.; Nyawale, H.; Majinge, D.; Hyera, F.; Jaka, H.; Mtemisika, C.; Michael, F. Hepatitis B virus infection, associated factors, knowledge and vaccination status among household contacts of hepatitis B index cases in Mwanza, Tanzania. IJID Reg. 2024, 10, 168–173. [Google Scholar] [CrossRef]
- World Health Organization. Guidance on Prevention of Viral Hepatitis B and C among People Who Inject Drugs; World Health Organization: Geneva, Switzerland, 2012. [Google Scholar]
- Melhem, N.M.; Rahhal, N.; Charide, R.; Kreidieh, K.; El-Khatib, R. Human immunodeficiency virus and viral hepatitis among high-risk groups: Understanding the knowledge gap in the Middle East and North Africa Region. World J. Hepatol. 2015, 7, 2619. [Google Scholar] [CrossRef] [PubMed]
- Hagan, O.C.; Nsiah, P.; Obiri-Yeboah, D.; Yirdong, F.; Annan, I.; Eliason, S.; Nuvor, S.V. Impact of universal childhood vaccination against hepatitis B in Ghana: A pilot study. J. Public Health Afr. 2018, 9, 92–95. [Google Scholar] [CrossRef] [PubMed]
- Barro, M.; Valea, D.; Ouermi, S.A.; Sessouma, S.; Sanogo, B.; Ouattara, I.A.B.; Ouedraogo, A.S.; Nacro, B.; Moyen, G. Serological profile of hepatitis B in children after the introduction of its vaccination in Burkina Faso. Pediatr. Rep. 2019, 11, 8248. [Google Scholar] [CrossRef]
- Teshome, S.; Biazin, H.; Tarekegne, A.; Abebe, T.; Bekele, F.; Mihret, A.; Aseffa, A.; Howe, R. Antibody response against hepatitis B virus after vaccination and seroprevalence of HBV in children in Addis Ababa. Ethiop. Med. J. 2019, 57, 167–173. Available online: https://pesquisa.bvsalud.org/portal/resource/pt/afr-201259 (accessed on 30 July 2021).
- Shatat, H.; Kotkat, A.; Farghaly, A.; Omar, S.; Zayton, S. A study of hepatitis B vaccine efficacy 10 years after compulsory vaccination in Egypt. J. Egypt. Public Health Assoc. 2005, 80, 495–508. [Google Scholar]
- Hamid, A.T.A.; Said, Z.N. Persistence of protection to hepatitis B vaccine and response to booster dose among children and adolescents in Dakahleya-Egypt. Egypt. J. Immunol. 2014, 21, 13–26. [Google Scholar]
- Mele, A.; Tancredi, F.; Romano, L.; Giuseppone, A.; Colucci, M.; Sangiuolo, A.; Lecce, R.; Adamo, B.; Tosti, M.E.; Taliani, G. Effectiveness of hepatitis B vaccination in babies born to hepatitis B surface antigen-positive mothers in Italy. J. Infect. Dis. 2001, 184, 905–908. [Google Scholar] [CrossRef]
- Hashemi, S.; Moghadami, M.; Bagheri, L.K.; Alborzi, A.; Mahboudi, A. The efficacy of hepatitis B vaccination among school age children in Southern Iran. Iran. Red Crescent Med. J. 2010, 12, 45–48. [Google Scholar]
- Avazova, D.; Kurbanov, F.; Tanaka, Y.; Sugiyama, M.; Radchenko, I.; Ruziev, D.; Musabaev, E.; Mizokami, M. Hepatitis B virus transmission pattern and vaccination efficiency in Uzbekistan. J. Med. Virol. 2008, 80, 217–224. [Google Scholar] [CrossRef]
- Okwakol, O.S. Prevalence of Immune Non-Response to Hepatitis B Virus Vaccine among Secondary School Students in Kumi District, Eastern Uganda; Makerere University: Kampala, Uganda, 2021. [Google Scholar]
- Reda, A.; Arafa, M.; Youssry, A.; Wandan, E.; Ab de Ati, M.; Daebees, H. Epidemiologic evaluation of the immunity against hepatitis B in Alexandria, Egypt. Eur. J. Epidemiol. 2003, 18, 1007–1011. [Google Scholar] [CrossRef]
- Lubell-Doughtie, P.; Bhatt, S.; Wong, R.; Shankar, A.H. Transforming Rapid Diagnostic Tests for Precision Public Health: Open Guidelines for Manufacturers and Users. JMIR Biomed. Eng. 2022, 7, e26800. [Google Scholar] [CrossRef] [PubMed]
- Park, C.; Ngo, H.; Lavitt, L.R.; Karuri, V.; Bhatt, S.; Lubell-Doughtie, P.; Shankar, A.H.; Ndwiga, L.; Osoti, V.; Wambua, J.K. The design and evaluation of a mobile system for rapid diagnostic test interpretation. Proc. ACM Interact. Mob. Wearable Ubiquitous Technol. 2021, 5, 1–26. [Google Scholar] [CrossRef]
Variables | 15–17 Years, n = 288 | 0–5 Years, n = 501 | Combined, n = 789 |
---|---|---|---|
Age Mean (SD) | 16.18 (0.8836) | 2.93 (1.3) | |
Gender n (%) | |||
Male | 149 (51.74) | 242 (48.3) | 391 (49.55) |
Female | 139 (48.26) | 259 (51.7) | 398 (50.44) |
Doses | 15–17 years, n = 259 | 0–5 years, n = 501 | Combined, n = 760 |
One | 26 (10.04) | 26 (5.19) | 52 (6.84) |
Two | 45 (17.37) | 34 (6.79) | 79 (10.39) |
Three | 188 (72.59) | 441 (88.02) | 629 (82.76) |
Variables | 15–17 Years, n = 288 | 0–5 Years, n = 501 | Combined, n = 789 |
---|---|---|---|
HBV markers combo n (%) | |||
HBsAg | 8 (2.78) | 4 (0.8) | 12 (1.52) |
HBsAb | 53 (18.4) | 166 (33.1) | 219 (27.75) |
HBeAg | 3 (1.04) | 4 (0.8) | 7 (0.88) |
HBeAb | 2 (0.69) | 3 (0.6) | 5 (0.63) |
HBcAb | 6 (2.08) | 0 (0) | 6 (0.76) |
Infection status n (%) | |||
Never been exposed | 277 (96.18) | 497 (99.2) | 774 (98.09) |
Ever been exposed | 11 (3.8) | 4 (0.80) | 15 (1.9) |
Exposed and resolved | 3 (1.04) | 0 (0) | 3 (0.38) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Muwanda, F.; Kiyonga, E.; Nambafu, J.; Turyamubona, A.; Kafeero, H.M.; Kigozi, E.; Babikako, H.M.; Wekiya, E.; Mboowa, G.; Kateete, D.P.; et al. Serological Status of Vaccine and Hepatitis B Virus Exposure Among Children Under 5 and Aged 15–17 Years in Kampala, Uganda. Livers 2024, 4, 550-561. https://doi.org/10.3390/livers4040039
Muwanda F, Kiyonga E, Nambafu J, Turyamubona A, Kafeero HM, Kigozi E, Babikako HM, Wekiya E, Mboowa G, Kateete DP, et al. Serological Status of Vaccine and Hepatitis B Virus Exposure Among Children Under 5 and Aged 15–17 Years in Kampala, Uganda. Livers. 2024; 4(4):550-561. https://doi.org/10.3390/livers4040039
Chicago/Turabian StyleMuwanda, Fahad, Edward Kiyonga, Joan Nambafu, Agnes Turyamubona, Hussein Mukasa Kafeero, Edgar Kigozi, Harriet Mupere Babikako, Enock Wekiya, Gerald Mboowa, David Patrick Kateete, and et al. 2024. "Serological Status of Vaccine and Hepatitis B Virus Exposure Among Children Under 5 and Aged 15–17 Years in Kampala, Uganda" Livers 4, no. 4: 550-561. https://doi.org/10.3390/livers4040039
APA StyleMuwanda, F., Kiyonga, E., Nambafu, J., Turyamubona, A., Kafeero, H. M., Kigozi, E., Babikako, H. M., Wekiya, E., Mboowa, G., Kateete, D. P., Sendagire, H., Norman, P. J., & Bagaya, B. S. (2024). Serological Status of Vaccine and Hepatitis B Virus Exposure Among Children Under 5 and Aged 15–17 Years in Kampala, Uganda. Livers, 4(4), 550-561. https://doi.org/10.3390/livers4040039